Jon-Emile S. Kenny MD [@heart_lung] “Let us try to assume our fundamental ambiguity.” -Simone de Beauvoir When the pre-peer review RECOVERY trial was released in mid-June of this year, clinicians lost equipoise to enroll hospitalized patients receiving at least oxygen for COVID-19 into trials including a treatment arm without corticosteroids. This brought to an early-halt three randomized trials evaluating corticosteroids in hospitalized patients with COVID-19-associated lung injury. Two of these three trials studied hydrocortisone while the third evaluated dexamethasone at a higher dosing regimen than RECOVERY. Recall that studies up to and including RECOVERY suggested that corticosteroids most-benefited COVID-19 patients receiving mechanical ventilation. Accordingly, the three, halted randomized trials are briefly summarized below in rough order of COVID-19 severity at randomization, based on respiratory organ support. Critically, the definition of ‘severe’ COVID-19 is non-standardized. Nevertheless, based on the